Seed Innovations Ltd

Investee Company Update: Little Green Pharma Ltd

RNS Number : 7759G
Seed Innovations Limited
31 March 2022

Seed Innovations Ltd / AIM: SEED / Sector: Closed End Investments

31 March 2022

SEED Innovations Limited ("SEED" or the "Company")

Investee Company Update: Little Green Pharma Ltd

SEED Innovations Ltd, the AIM quoted company investing in fast growing and industry leading businesses with a focus on the medical cannabis, health and wellness space, is pleased to note an announcement released by Telaleaf Health Inc. ('Telaleaf'), a telemedicine company, who are entering into a joint sponsorship of a second certificate course in medical cannabis for healthcare professionals in Germany with portfolio company, Little Green Pharma Ltd ('LGP').

 SEED owns a holding of 7,324,796 ordinary shares in LGP representing 3.1% of LGP's issued share capital.  


The following extract from the announcement is set out without material changes or adjustments  and  the announcement in full can be accessed from the link below this section.


"Telaleaf and Little Green Pharma Sponsor Second Session of Certificate Course in Medical Cannabis for Doctors in Germany


Berlin, Germany, March 28, 2022 --( Telaleaf Health Inc. ("Telaleaf" or the "Company"), a telemedicine company transforming the delivery of cannabis care to patients, is pleased to announce its joint sponsorship together with leading global medical cannabis company Little Green Pharma Ltd. (or "LGP"), of the second certificate course for doctors, pharmacists and relevant professionals interested in the therapeutic application of cannabis medicines.


The course titled, "The A-Z of cannabis-based therapy: Basics and practical use of cannabis-based drugs in medical practice and pharmacy" is hosted by Dresden International University and kicked off its inaugural session September 30, 2021. The course is developed and instructed by world-renown medical cannabis experts Dr. Franjo Grotenhermen, Dr. Kirsten Müller-Vahl and Dr. Dennis Stracke - delivering 82 lessons over a 12-week period. The second session of this leading-edge course began March 24, 2022.


The course is a comprehensive, practice-oriented and interdisciplinary certificate course for doctors, providing in-depth knowledge of all aspects of cannabis-based therapy, which doctors and pharmacists require for appropriate and responsible therapeutic use of all cannabis-based drugs currently available for prescription. Upon completion of the course, advanced training points are awarded by the Saxon State Medical Association for those who have the appropriate professional affiliation.


The many years of individual and combined clinical, practical and scientific experience of the lecturers is of immense value to the course participants, as well as their excellent knowledge of emerging cannabis laws and the current political and legal landscape in Germany, Europe and beyond.


"As a response to the popular demand by doctors for participation in this course, we are pleased to announce that there will be 2 more courses this year. The next course is scheduled to start in the fall 2022 and the course after next is scheduled to start in December 2022," said Eva Allouche, Telaleaf co-Founder and Chief Operating Officer.

For more information and to register for the next courses, go to:


About Telaleaf

Telaleaf is a telemedicine company transforming the delivery of cannabis care by connecting patients to expert doctors, trained in cannabis-based medicine, who conduct virtual medical visits and provide personalized treatment plans. Our aim is to improve patient outcomes, by improving the patient experience with high quality treatment, ease of access and expert-led training to doctors, for the most advanced virtual care in cannabis medicine.


About Little Green Pharma

Little Green Pharma is a leading global medicinal cannabis business with key production assets in Australia and Europe. Our goal is to improve patient access to GMP-grade cannabis medicines around the world and transform lives for the better. To achieve this, we prioritize assisting doctors with ongoing education on treatment benefits and with the prescribing process to make it as simple as possible.

-   Ends -


For further information on the Company please visit      or contact: 




Ed McDermott /

Lance de Jersey

SEED Innovations Ltd

Email:     [email protected]


James Biddle /Roland Cornish

Beaumont Cornish Limited,



Tel: +44 (0) 207 628 3396

Isabella Pierre /Damon Heath

Shard Capital Partners LLP


Tel: +44 (0)20 7186 9927

Catherine Leftley /Isabelle Morris

St Brides Partners Ltd,

Financial PR


Email: [email protected]





SEED Innovations is an AIM quoted investment company focused primarily on disruptive high growth life sciences and technology businesses particularly within the medical cannabis arena. The Company's strategy is to identify early-stage opportunities that have an upcoming investment catalyst and grow its portfolio in terms of value whilst limiting the number of investee companies to a level where relevant time can be devoted to each.



This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.